Novel serum tumor marker, RCAS1, in pancreatic diseases

doi:10.3748/wjg.v11.i33.5199

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 33

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1733)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

206

HTML

1128

Figures (1-1)

225

Tables (1-4)

174

Sum=1733

Sep 7, 2005 (publication date) through Nov 20, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Sep 7, 2005; 11(33): 5199-5202
Published online Sep 7, 2005. doi: 10.3748/wjg.v11.i33.5199

Novel serum tumor marker, RCAS1, in pancreatic diseases

Koji Yamaguchi, Munechika Enjoji, Manabu Nakashima, Makoto Nakamuta, Takashi Watanabe, Masao Tanaka

Koji Yamaguchi, Masao Tanaka, Department of Surgery and Oncology, Graduate School of Medicine, Kyushu University, Japan

Munechika Enjoji, Makoto Nakamuta, Medicine Bioregulatory Sciences, Graduate School of Medical Sciences, Kyushu University, Japan

Manabu Nakashima, Takashi Watanabe, Department of Molecular Immunology, Medical Institute of Bioregulation, Faculty of Medicine, Kyushu University, Japan

Author contributions: All authors contributed equally to the work.

Correspondence to: Koji Yamaguchi, MD, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan

Telephone: +81-92-642-5438 Fax: +81-92-642-5457

Received: November 12, 2004
Revised: February 15, 2005
Accepted: February 18, 2005
Published online: September 7, 2005

Abstract

AIM: As tumor markers for pancreatic carcinoma, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma.

METHODS: A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA (highly specific for pancreatic cancer) and CA 19-9 (highly sensitive for pancreatic cancer), in 48 patients with pancreatic exocrine tumors.

RESULTS: When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone (55%) was higher than that of CEA alone (27%) and the specificity of RCAS1 alone (92%) was greater than that of CA19-9 alone (78%). When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 (95%) was superior to those of CA19-9 alone (78%), RCAS1 alone (55%, P = 0.002), CEA alone (27%) (P<0.001), RCAS1 and CEA (59%) and CA19-9 and CEA (82%).

CONCLUSION: These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma.

Keywords: RCAS1; CEA; CA19-9; Pancreatic diseases